HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibiotic bedaquiline effectively targets growth, survival and tumor angiogenesis of lung cancer through suppressing energy metabolism.

Abstract
Tumor angiogenesis plays essential roles during lung cancer progression and metastasis. Therapeutic agent that targets both tumor cell and vascular endothelial cell may achieve additional anti-tumor efficacy. We demonstrate that bedaquiline, a FDA-approved antibiotic drug, effectively targets lung cancer cells and angiogenesis. Bedaquiline dose-dependently inhibits proliferation and induces apoptosis of a panel of lung cancer cell lines regardless of subtypes and molecular heterogeneity. Bedaquiline also inhibits capillary network formation of human lung tumor associated-endothelial cell (HLT-EC) on Matrigel and its multiple functions, such as spreading, proliferation and apoptosis, even in the presence of vascular endothelial growth factor (VEGF). We further demonstrate that bedaquiline acts on lung cancer cells and HLT-EC via inhibiting mitochondrial respiration and glycolysis, leading to ATP reduction and oxidative stress. Consistently, oxidative damage on DNA, protein and lipid were detected in cells exposed to bedaquiline. Importantly, the results obtained in in vitro cell culture are reproducible in in vivo xenograft lung cancer mouse model, confirming that bedaquiline suppresses lug tumor growth and angiogenesis, and increases oxidative stress. Our findings demonstrating that energy depletion is effectively against lung tumor cells and angiogenesis. Our work also provide pre-clinical evidence to repurpose antibiotic bedaquiline for lung cancer treatment.
AuthorsXiaomu Wu, Fajiu Li, Xiaojiang Wang, Chenghong Li, Qinghua Meng, Chuanhai Wang, Jie Huang, Shi Chen, Ziyang Zhu
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 495 Issue 1 Pg. 267-272 (01 01 2018) ISSN: 1090-2104 [Electronic] United States
PMID29107691 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2017 Elsevier Inc. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Diarylquinolines
  • bedaquiline
  • Adenosine Triphosphate
Topics
  • A549 Cells
  • Adenosine Triphosphate (metabolism)
  • Animals
  • Anti-Bacterial Agents (administration & dosage)
  • Antineoplastic Agents (administration & dosage)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Diarylquinolines (administration & dosage)
  • Dose-Response Relationship, Drug
  • Energy Metabolism (drug effects)
  • Humans
  • Lung Neoplasms (drug therapy, metabolism, pathology)
  • Mice
  • Mice, SCID
  • Neovascularization, Pathologic (drug therapy, metabolism, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: